secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001157523-22-001500
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress
--------------------------------------------------------------------------------

- Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).
- 2022 revenue guidance cut to $14.8-15.4B (prev $15.0-15.6B) due to FX; all other guidance affirmed.
- Opioid litigation: substantial progress toward nationwide settlement; agreement in principle with NY AG; reserve updated.
- AUSTEDO U.S. revenue +30% YoY, on track for ~$1B annual; AJOVY gains share in U.S., Europe, Japan.
- Cash from operations $543M; free cash flow $685M; non-GAAP tax rate outlook revised to 12-14%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/0001157523-22-001500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/a52958636.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer